SEC Tracker
Get the app

Pulmatrix PULM

Pulmatrix FY 2024: revenue $7.8M, up 7%; diluted EPS −$2.62

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Pulmatrix reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$7.8M+7% from $7.3M in FY 202310-K income statement, on EDGAR
  2. Net income−$9.6MAgainst −$14.1M in FY 202310-K income statement, on EDGAR
  3. Diluted EPS−$2.62Against −$3.87 in FY 202310-K income statement, on EDGAR
  4. Cash and cash equivalents$9.5M−50% from $19.2M in FY 202310-K balance sheet, on EDGAR
  5. Cash from operations−$10.7MAgainst −$16.0M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Pulmatrix files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Curis CRIS public float $25M, Jun 30, 2025
  2. Scynexis SCYX public float $26M, Jun 30, 2025
  3. Palatin Technologies PTN public float $26M, Dec 31, 2025
  4. Kala Bio KALA public float $25M, Jun 30, 2025
  5. Lexaria Bioscience LEXX public float $25M, Feb 28, 2025, over 18 months old